CL2018002335A1 - Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1 - Google Patents

Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1

Info

Publication number
CL2018002335A1
CL2018002335A1 CL2018002335A CL2018002335A CL2018002335A1 CL 2018002335 A1 CL2018002335 A1 CL 2018002335A1 CL 2018002335 A CL2018002335 A CL 2018002335A CL 2018002335 A CL2018002335 A CL 2018002335A CL 2018002335 A1 CL2018002335 A1 CL 2018002335A1
Authority
CL
Chile
Prior art keywords
acetylcholine receptor
positive allosteric
allosteric modulators
muscarinic acetylcholine
compositions
Prior art date
Application number
CL2018002335A
Other languages
English (en)
Inventor
Craig W Lindsley
P Jeffrey Conn
Darren W Engers
Katrina A Bollinger
Julie L Engers
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of CL2018002335A1 publication Critical patent/CL2018002335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN MODULADORES ALOSTÉRICOS POSITIVOS DEL RECEPTOR DE ACETILCOLINA MUSCARÍNICO M1(mAChR M1), COMPOSICIONES FARMACÉUTICAS QUE INCLUYEN LOS COMPUESTOS, Y MÉTODOS PARA USAR LOS COMPUESTOS Y COMPOSICIONES PARA TRATAR TRASTORNOS NEUROLÓGICOS, TRASTORNOS PSIQUIÁTRICOS O COMBINACIÓN DE LOS MISMOS.
CL2018002335A 2016-02-16 2018-08-14 Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1 CL2018002335A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296012P 2016-02-16 2016-02-16
US201662402438P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
CL2018002335A1 true CL2018002335A1 (es) 2019-02-01

Family

ID=59626207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002335A CL2018002335A1 (es) 2016-02-16 2018-08-14 Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1

Country Status (15)

Country Link
US (1) US11111251B2 (es)
EP (1) EP3416639B1 (es)
JP (1) JP2019504901A (es)
KR (1) KR20180110132A (es)
CN (1) CN109069491A (es)
AU (1) AU2017221404A1 (es)
BR (1) BR112018016689A2 (es)
CA (1) CA3014791A1 (es)
CL (1) CL2018002335A1 (es)
EA (1) EA201891854A1 (es)
IL (1) IL261058A (es)
MA (1) MA44253A (es)
MX (1) MX385975B (es)
PH (1) PH12018501731A1 (es)
WO (1) WO2017143041A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000554T1 (it) * 2016-09-02 2020-11-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
HUE063823T2 (hu) * 2017-06-20 2024-02-28 Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként
KR102658949B1 (ko) * 2017-06-20 2024-04-18 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
JP7110338B2 (ja) * 2017-10-27 2022-08-01 スヴェン・ライフ・サイエンシーズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーターである多環式アミド類
WO2019089676A1 (en) 2017-10-31 2019-05-09 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
IL276411B2 (en) 2018-02-02 2024-04-01 Univ Vanderbilt M4 muscarinic acetylcholine receptor antagonists
WO2019241467A1 (en) * 2018-06-13 2019-12-19 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US11970483B2 (en) 2018-09-28 2024-04-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12162864B2 (en) 2018-09-28 2024-12-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
EP3643711A1 (en) * 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
US12065433B2 (en) 2018-10-24 2024-08-20 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
CA3155864A1 (en) * 2019-10-04 2021-04-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608079A (en) 1983-08-02 1986-08-26 American Cyanamid Company Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
KR20010102543A (ko) 1999-03-09 2001-11-15 로렌스 티. 마이젠헬더 항바이러스제로서의4-옥소-4,7-디히드로-티에노[2,3-ｂ]피리딘-5-카르복스아미드
AR028385A1 (es) 2000-04-28 2003-05-07 Acadia Pharm Inc Agonistas muscarinicos
CA2462453C (en) * 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
PT2512243E (pt) 2009-12-17 2016-06-08 Merck Sharp & Dohme Moduladores alostéricos positivos de recetor de quinolina amida m1
EP2582676B1 (en) 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
WO2012158474A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
EP3097094B1 (en) 2014-01-22 2020-01-15 F.Hoffmann-La Roche Ag Fluoro-naphthyl derivatives
JP6571077B2 (ja) * 2014-06-13 2019-09-04 武田薬品工業株式会社 含窒素複素環化合物
WO2016009297A1 (en) * 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016029454A1 (en) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
SMT202000554T1 (it) 2016-09-02 2020-11-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1

Also Published As

Publication number Publication date
EP3416639A4 (en) 2019-07-03
EP3416639B1 (en) 2022-06-08
WO2017143041A1 (en) 2017-08-24
MX385975B (es) 2025-03-18
MX2018009952A (es) 2018-11-29
AU2017221404A1 (en) 2018-08-23
JP2019504901A (ja) 2019-02-21
BR112018016689A2 (pt) 2019-02-12
US11111251B2 (en) 2021-09-07
CA3014791A1 (en) 2017-08-24
CN109069491A (zh) 2018-12-21
IL261058A (en) 2018-10-31
EA201891854A1 (ru) 2019-01-31
US20210230180A1 (en) 2021-07-29
KR20180110132A (ko) 2018-10-08
EP3416639A1 (en) 2018-12-26
MA44253A (fr) 2018-12-26
PH12018501731A1 (en) 2019-06-17

Similar Documents

Publication Publication Date Title
CL2018002335A1 (es) Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
MX2017001512A (es) Compuestos activos hacia bromodominios.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CL2016002751A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
UY37098A (es) Moduladores de ror-gamma
CL2018000883A1 (es) Moduladores del receptor x farnesoide
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
MX2017014375A (es) Moduladores del ccr2.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
BR112016025470A2 (pt) ?hdl terapêutico?
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
ECSP21016032A (es) Inhibidores de la interacción proteína-proteína keap1-nrf2
CL2016002497A1 (es) “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct
AR109752A1 (es) Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2016000726A1 (es) Derivados de 4-azaindol
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
MX394089B (es) Nuevos derivados de xantina sustituidos.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino